Description: Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Home Page: www.trawspharma.com
12 Penns Trail
Newtown,
PA
18940
United States
Phone:
267 759 3680
Officers
| Name | Title |
|---|---|
| Mr. Mark Patrick Guerin CPA | Chief Financial Officer |
| Dr. Victor Moyo M.D. | Chief Medical Officer of Oncology |
| Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | Executive Chairman |
| Dr. Werner Cautreels Ph.D. | CEO & Director |
| Dr. Nikolay Savchuk Ph.D. | COO & Director |
| Dr. Robert R. Redfield M.D. | Chief Medical Officer |
| Dr. Charles David Pauza Ph.D. | Chief Scientific Officer of Virology |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6745 |
| Price-to-Sales TTM: | 39.1656 |
| IPO Date: | 2001-01-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 17 |